Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Pancreatic Neoplasms 44Triple Negative Breast Neoplasms 20Breast Neoplasms 16Carcinoma, Non-Small-Cell Lung 14Neoplasm Metastasis 10Lung Neoplasms 10Squamous Cell Carcinoma of Head and Neck 8Parkinson Disease 4, Autosomal Dominant Lewy Body 7Neoplasms 6Adenocarcinoma 6Cholangiocarcinoma 5Stomach Neoplasms 4Gallbladder Neoplasms 4Esophageal Squamous Cell Carcinoma 4Esophageal Neoplasms 4Biliary Tract Neoplasms 4Uterine Cervical Neoplasms 3Recurrence 3Pancreatic Adenocarcinoma 3Ovarian Neoplasms 3Head and Neck Neoplasms 3Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Colorectal Neoplasms 3Small Cell Lung Carcinoma 2Sarcoma 2Rectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Pancreatic Ductal 2Carcinoma, Hepatocellular 2

Interventions

Gemcitabine 5Taxes 3Albumin-Bound Paclitaxel 3Radiotherapy, Intensity-Modulated 2Radiotherapy 2Oxaliplatin 2Losartan 2Leucovorin 2Irinotecan 2Fluorouracil 2130-nm albumin-bound paclitaxel 2tocilizumab 1selicrelumab 1niraparib 1durvalumab 1dehydroftorafur 1cobimetinib 1atezolizumab 1X-Rays 1Tiragolumab 1Standard of Care 1Specimen Handling 1Radiation 1Panitumumab 1Pancreaticoduodenectomy 1PEGPH20 1Optical Imaging 1Nivolumab 1Metformin 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Pancreatic Adenocarcinoma × Albumin-Bound Paclitaxel × 1 year × Clear all
NCT05624918 2026-04-08

A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

Big Ten Cancer Research Consortium

Phase 2 Recruiting
38 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

NCT02336087 2026-02-04

Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery

City of Hope Medical Center

Phase 1 Active not recruiting
21 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

NCT04539808 2026-01-14

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

OHSU Knight Cancer Institute

Phase 2 Active not recruiting
42 enrolled 13 charts
Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡